- Home
- DGICB vs OCGN Comparison
DGICB vs OCGN Comparison
Compare DGICB & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DGICB | OCGN |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | United States |
| Employees | 851 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 576.5M | 474.8M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | DGICB | OCGN |
|---|---|---|
| Price | $15.80 | $1.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 1.7K | ★ 8.0M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $978,014,322.00 | N/A |
| Revenue This Year | $2.26 | N/A |
| Revenue Next Year | N/A | $1,718.38 |
| P/E Ratio | $8.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.87 | $0.97 |
| 52 Week High | $29.99 | $2.73 |
Technical Indicators
Market Signals| Indicator | DGICB | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 31.71 | 42.51 |
| Support Level | $15.00 | $0.97 |
| Resistance Level | $17.93 | $1.49 |
| Average True Range (ATR) | 1.01 | 0.06 |
| MACD | -0.76 | 0.00 |
| Stochastic Oscillator | 3.40 | 76.92 |
Price Performance
Historical ComparisonAbout DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").